Sage Therapeutics Inc (FRA:SG7)
€ 5.452 0.102 (1.91%) Market Cap: 325.18 Mil Enterprise Value: -211.07 Mil PE Ratio: 0 PB Ratio: 0.61 GF Score: 49/100

SAGE Therapeutics Inc at Cowen Health Care Conference Transcript

Mar 06, 2023 / 03:30PM GMT
Release Date Price: €38.68 (-1.63%)
Ritu Subhalaksmi Baral
TD Cowen, Research Division - MD & Senior Biotechnology Analyst

We're going to go ahead and get started. Thank you, everyone, for joining us for the Sage fireside chat at the TD Cowen Healthcare Conference this year.

With us, we have the CEO of Sage, Barry Greene, who most of you, I think, know quite well. I'm Ritu Baral, covering analyst -- moderating.

Questions & Answers

Ritu Subhalaksmi Baral
TD Cowen, Research Division - MD & Senior Biotechnology Analyst

Barry, do you want to give us just a few minutes on where we are in zuranolone's -- well, where Sage is, but also specifically where we are in zuranolone's clinical development and NDA review patent?

Barry E. Greene
Sage Therapeutics, Inc. - President, CEO & Director

Absolutely, Ritu. First of all, thanks for having us, and I appreciate the organizers for TD Cowen putting us in this enormous room that we're in. So thank you for that. It took me longer to get here than it took to get from my home to the

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot